Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran Autogene, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence by 49% within five years…
Merck & Co. and Moderna Inc. reported that their personalized mRNA cancer vaccine intismeran, combined with the immunotherapy Keytruda, kept melanoma from returning in a large late-stage Phase 3 trial…
On August 15, Anthropic CEO Dario Amodei argued that AI companies will earn trust by curing diseases, and the past week showcased advances in AI-driven medicine, including Moderna and Merck's INTerpat…
Moderna and Merck's experimental mRNA cancer vaccine intismeran autogene met its primary endpoint of recurrence-free survival and a key secondary endpoint in a Phase 3 trial of 1,137 patients with res…